REC Ref No.	IRAS No.	Name of Trial	Date First	Date Site	Date Site	HRA Approval	Date Site	Date Site	Non-	Date Site	Reasons for
			Participant Recruited		Selected	Date	Confirmed By Sponsor	Confirmed	Confirmation Status		delay correspond to:
21/NW/0352	307220	A PHASE 1B, ADAPTIVE, MULTI-CENTER,RANDOMIZED, DOUBLE BLIND, PLACEBOCONTROLLED, PARALLEL DESIGN STUDY TO INVESTIGATE THE SAFETY, TOLERABILITY,PHARMACOKINETICS AND PHARMACODYNAMICSOF RO7486967 IN PARTICIPANTS WITH EARLY IDIOPATHIC PARKINSON'S DISEASE		21/12/2021	23/12/2021						
20/LO/0790	280190	An open-label, single arm, roll-over study to provide continued treatment with darolutamide in participants who were enrolled in previous Bayer-sponsored studies		16/12/2021	17/12/2021	30/06/2020					
21/WA/0294	302661	A 2-Stage (Open-Label Run-in followed by Randomized Withdrawal), Double-Blind, Placebo-Controlled, Phase 2 study of Setmelanotide in Patients with Specific Gene Defects in the Melanocortin-4 Receptor Pathway		20/12/2021	20/12/2021						
21/LO/0694	1003775	A randomised phase II study comparing 3 vs 6 cycles of platinum-based chemotherapy prior to maintenance avelumab in advanced urothelial cancer.		23/09/2021	15/12/2021	19/11/2021					
21/SC/0277	1003812	FOxTROT 2: A phase III randomized trial evaluating neoadjuvant chemotherapy in older and/or frail patients with locally advanced but operable colon cancer		27/09/2021	23/11/2021	03/11/2021					
21/SC/0256	1003801	Single-Arm, Phase 2 Study of Valemetostat Tosylate Monotherapy in Subjects with Relapsed/Refractory Peripheral T-Cell Lymphoma		29/03/2021	18/11/2021						
19/EE/0348	261447	A RANDOMIZED PHASE II TRIAL ASSESSING TRIMODALITY THERAPY WITH OR WITHOUT ADJUVANT DURVALUMAB (MEDI4736) TO TREAT PATIENTS WITH MUSCLE-INVASIVE BLADDER CANCER		19/10/2021	26/11/2021						
19/EE/0369	257226	Melanoma Margins Trial (MelMarT): A Phase III, multi-centre, multi-national randomised control trial investigating 1cm v 2cm wide excision margins for primary cutaneous melanoma		28/10/2021	17/12/2021						
19/LO/1918	271688	An open label phase Ib dose finding study of BI 836880 in combination with ezabenlimab to characterize safety, tolerability, pharmacokinetics, pharmacodynamics and efficacy in patients with locally advanced or metastatic non-squamous Non-Small Cell Lung Cancer and in other solid tumors		28/10/2021	08/11/2021	28/09/2021					
21/LO/0693	1004042	SPLASH: Study Evaluating Metastatic Castrate Resistant Prostate Cancer Treatment Using 177Lu-PNT2002 PSMA Therapy after Second-line Hormonal Treatment.		04/10/2021	14/10/2021						NHS Trust

a . // a /a == a	I	[1.5]	T			1	1	1	1	1
21/LO/0776	1004145	A Phase 2a Open-Label Study in Infants with REspiratory	11/10/202	03/12/2021						
		Syncytial VIRus Lower RespirAtory Tract Infection, Followed								
		by a DoubLe-blind, Placebo controlled Part, to Evaluate the								
		Safety, Tolerability, Pharmacokinetics and Antiviral Effect of								
0.4 // 0./0.000	004400	RV521 (REVIRAL 1)	40/00/000							
21/LO/0632	301120	A Multicenter, Randomized, Double-Blind, Placebo-	10/09/202	30/11/2021						
		Controlled Phase III Study of Fuzuloparib Combined with								
		Abiraterone Acetate and Prednisone (AA-P) versus Placebo								
		Combined with AA-P as First-Line Treatment in Patients with								
		Metastatic Castration-Resistant Prostate Cancer								
21/EE/0242	1004172	An open-label dose-escalation study evaluating the safety,	05/11/202	1 05/11/2021						
		pharmacokinetics and antiviral activity of IMC-M113V inHLA-								
		A*02:01 positive subjects with chronic HIV infection who are								
		virologically suppressed								
21/WS/0127	303268	Safety and Effectiveness Analysis of stent assisted coiling	07/10/202	1 27/10/2021						Sponsor
		with LVIS® Evo™ and HydroCoil® Embolic System in								
		ANeurysm Treatment								
21/YH/0175	298368	PETNECK 2: PET-CT guided, symptom-based, patient-	05/10/202	1 25/11/2021	16/09/2021					
		initiated surveillance versus clinical follow-up in head and								
		neck								
		cancer	0.7/0.7/0.00							
21/FT/0124	299347	A phase III, multi-center, open-label, randomized study of	05/07/202	1 18/10/2021						Sponsor
		oral asciminib versus Investigator selected TKI in patients								
		with newly diagnosed Philadelphia Chromosome Positive								
04/1 0/0755	000000	Chronic Myelogenous Leukemia in Chronic Phase	00/00/000	1 40/44/0004		0.4/4.4/0.004	00/04/0000		00/04/0000	
21/LO/0755	300992	An open-label, multi-center, phase 2 basket study to assess	29/09/202	1 10/11/2021		24/11/2021	06/01/2022		06/01/2022	
		efficacy, safety and pharmacokinetics of iptacopan (LNP023)								
		in participants with autoimmune benignhematological disorders								
21/LO/0730	304373	Open Label Extension Study for Patients with Early	07/10/202	1 08/11/2021						
21/20/0730	304373	Alzheimer's Disease (AD) Enrolled in Study ANAVEX2-	07/10/202	1 00/11/2021						
		73-AD-004								
21/EE/0064	288875	A phase 1B/3 double-blind, randomized, active-controlled, 3-	29/06/202	0 01/10/2021						Sponsor
	-555.5	stage, biomarker adaptive study of tazemetostat or placebo								O p 000.
		in combination with lenalidomide plus rituximab in subjects								
		with relapsed/refractory follicular lymphoma.								
21/EM/0165	299780	A Randomized, Controlled, Multi-Center Study to Evaluate	06/09/202	1 23/09/2021		12/08/2021				Sponsor
		the Safety and Efficacy of Paltusotine in Subjects with								
		Acromegaly Treated with Long-acting Somatostatin Receptor								
		Ligands								
21/EM/0123	292892	AGAVE-201, A Phase 2, Open-label, Randomized,	18/05/202	25/10/2021	14/07/2021					Sponsor
		Multicenter Study to Evaluate the Efficacy, Safety and					1			
		Tolerability of Axatilimab at 3 Different Doses in Patients with								
		Recurrent or Refractory Active Chronic Graft Versus Host								
		Disease who have Received at least 2 Lines of Systemic								
		Therapy								
21/NE/0101	1003829	Phase 1/2a, Single Dose Study Investigating NTLA-5001 in	31/08/202	1 21/09/2021						Sponsor
		Subjects with Acute Myeloid Leukemia								

21/FT/0125	302263	A phase 3b, multi-center, open-label, treatment optimization study of oral asciminib in patients with Chronic Myelogenous Leukemia in chronic phase (CML-CP) previously treated with 2 or more tyrosine kinase inhibitors	25/11/2021	30/06/2021	13/09/2021		22/11/2021	22/11/2021	23/11/2021	Neither NHS Trust nor Sponsor
20/NW/0381	1003380	A Randomised, Open-Label, Parallel-Group, Pre surgical Study to Investigate the Biological Effects of AZD9833 in Women with ER-positive, HER2-negative Primary Breast Cancer		16/07/2021	26/10/2021					Sponsor
21/LO/0794	1004023	Treating Multiple Myeloma and Diffuse Large B Cell Lymphoma by Targeting the NF-κB Pathway with the First-in-Class GADD45β/MKK7 Inhibitor, DTP3		25/10/2021	15/12/2021	22/12/2021				
21/YH/0209	303827	A multi-centre randomised controlled trial examining the effects of temporarily suspending low-dose methotrexate treatment for two weeks after SARS-CoV-2 vaccine booster on vaccine response in immunosuppressed adults with inflammatory conditions, including a nested mechanistic substudy	09/11/2021	10/09/2021	13/09/2021		23/08/2021	01/11/2021	02/11/2021	Sponsor
21/EE/0158	298166	A Phase 3, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE-T)		25/03/2021	16/11/2021	11/08/2021				
21/EE/0157	298165	A Phase 3, Double-blind, Randomized, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Mitapivat in Subjects With Nonâ€"Transfusion-Dependent Alpha- or Beta-Thalassemia (ENERGIZE)		25/03/2021	16/11/2021	11/08/2021				
21/FT/0069	290279	A multicenter, randomized, double-blind, parallel group, placebo-controlled study to evaluate the efficacy and safety of iptacopan (LNP023) in complement 3 glomerulopathy	13/12/2021	24/08/2021	02/09/2021		10/11/2021	10/11/2021		Sponsor
21/FT/0086	300118	A multicenter, open-label, Phase IIb study to evaluate the efficacy, safety and pharmacokinetics of rilzabrutinib in patients with warm autoimmune hemolytic anemia		05/08/2021	05/08/2021	27/07/2021		19/11/2021		Sponsor
21/LO/0412	288722	Statins in Organ Donor Management An evaluation of the benefits of a single dose of Simvastatin given to potential organ donors declared dead by neurological criteria on outcomes in organ recipients	29/11/2021	23/07/2021	31/08/2021	28/06/2021	30/09/2021	30/09/2021	12/10/2021	Neither NHS Trust nor Sponsor
21/YH/0049	1003548	A PHASE III, DOUBLE-BLIND, MULTICENTER, RANDOMIZED STUDY OF ATEZOLIZUMAB (ANTIï€-PD-L1 ANTIBODY) VERSUS PLACEBO AS ADJUVANT THERAPY IN PATIENTS WITH HIGH-RISK MUSCLE-INVASIVE BLADDER CANCER WHO ARE CTDNA POSITIVE FOLLOWING CYSTECTOMY		01/07/2021	10/09/2021	05/05/2021	18/11/2021	19/11/2021	26/11/2021	Sponsor
21/NI/0107		An Open-label, Randomized, Phase 3 Study of MK-6482 in Combination with Lenvatinib (MK-7902) vs Cabozantinib for Second-line or Third-line Treatment in Participants with Advanced Renal Cell Carcinoma Who Have Progressed After Prior Anti- PD-1/L1 Therapy		03/03/2021	03/08/2021					Sponsor
21/LO/0529	292122	The HER2â€RADiCAL study (Response ADaptive CAre pLan) – Tailoring treatment for HER2 positive early breast cancer		16/07/2021	06/10/2021	02/09/2021	03/12/2021	20/12/2021		Sponsor

21/SC/0261	300456	···	29/10/2021	05/08/2021	31/08/2021	20/08/2021	11/10/2021	14/10/2021	27/10/2021	
		determine the longterm safety and character of immunological response to the ChAdOx1 nCoV-19								
		coronavirus vaccine								
21/WA/0165	289626	An Adaptive, Randomized, Placebo-controlled, Double-blind,		29/07/2021	09/08/2021	02/07/2021				Sponsor
		Multi-center Study of Oral FT-4202, a Pyruvate Kinase								
		Activator in Patients with Sickle Cell Disease (PRAISE)								
21/LO/0325	296099	A Phase 2b, Randomized, Double-Blind, Placebo-Controlled		17/09/2020	04/08/2021					Sponsor
		Study Evaluating the Effects of EDP-938 in Adult								
		Hematopoietic Cell Transplant Recipients with Acute Respiratory Syncytial Virus Infection of the Upper Respiratory								
		Tract								
21/SC/0187	1003729	A PHASE I/Ib GLOBAL, MULTICENTER, OPEN-LABEL	12/01/2022	24/06/2021	24/06/2021	13/07/2021		26/11/2021	26/11/2021	Sponsor
		UMBRELLA STUDY EVALUATING THE SAFETY AND								
		EFFICACY OF TARGETED THERAPIES IN SUBPOPULATIONS OF PATIENTS WITH								
		METASTATIC COLORECTAL CANCER (INTRINSIC)								
21/LO/0150	280335	A Randomised phase II trial of Enhancement of efficacy of		01/07/2021	24/08/2021	09/03/2021	15/11/2021	09/12/2021		Neither NHS Trust
		Atezolizumab by Radiotherapy in Metastatic urothelial								nor Sponsor
20/NE/0400	070450	carcinoma		05/00/2024	25/00/2024			02/42/2024	00/40/0004	Neither NHS Trust
20/NE/0198	278450	A Phase 1/2 Trial of the Synthetic Cannabinoid ART27.13 in Patients with Cancer Anorexia and Weight Loss		05/08/2021	25/08/2021			03/12/2021	06/12/2021	nor Sponsor
21/FT/0102	300762	A Phase 1, Open-label, Multi-part Study to Evaluate the		08/08/2021	27/08/2021					Sponsor
		Safety, Tolerability, Kinetics, Biodistribution and CNS Signal								
		of the Positron Emission Tomography Ligand 11C-BMS- 986196 in Healthy Participants after Intravenous								
		Administration and to Evaluate the Safety, Tolerability,								
		Kinetics, and CNS Signal Repeatability of 11C-BMS-986196								
		after Repeat Intravenous Administration in Participants with								
		Multiple Sclerosis								
21/WA/0227	295234	An Open-Label Long-term Follow-up Study to Evaluate the Effects of Sotatercept When Added to Background		11/03/2021	29/11/2021	31/08/2021				
		Pulmonary Arterial Hypertension (PAH) Therapy for the								
		Treatment of PAH								
21/LO/0648	1003773	A Phase 3, Randomized, Double-blind, Placebo controlled		11/03/2021	25/11/2021					
		Study to Evaluate Sotatercept When Added to Background								
		Pulmonary Arterial Hypertension (PAH) Therapy in Newly Diagnosed Intermediate- and High-risk PAH Patients								
21/NW/0221	1003973	A Phase 3 study of MK-4280A (coformulated favezelimab		30/06/2021	07/10/2021		01/12/2021	23/11/2021	01/12/2021	Neither NHS Trust
_ ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		[MK-4280] plus pembrolizumab [MK-3475]) Versus Standard			0171072021		0 17 1 2 2 2 1		• · · · · · · · · · · · · · · · · · · ·	nor Sponsor
		of Care in Previously Treated Metastatic PDL1 positive								
04/404/2005	004074	Colorectal Cancer		04/07/000:	40/00/2001					
21/NW/0206	291351	A Randomized, Double-blind, Placebo-controlled, Phase 2b study to Evaluate Safety and Efficacy of DUR-928 in		21/07/2021	16/08/2021					Sponsor
		Subjects with Alcoholic Hepatitis								
L			I		ı		L			

21/EM/0158	297323	A PHASE 3, RANDOMIZED, DOUBLE-BLIND, STUDY OF TALAZOPARIB WITH ENZALUTAMIDE VERSUS PLACEBO		23/04/2021	08/12/2021	13/08/2021	04/01/2022	11/01/2022		
		WITH ENZALUTAMIDE IN MEN WITH DDR GENE								
		MUTATED METASTATIC CASTRATION-SENSITIVE								
		PROSTATE CANCER								
24/FT/0040	202025		07/40/2024	24/05/2024	15/10/2021	07/04/2024	17/11/2021	17/11/2021	29/11/2021	
21/FT/0019	293935	· · · · · · · · · · · · · · · · · · ·	07/12/2021	24/05/2021	15/10/2021	07/04/2021	17/11/2021	17/11/2021	29/11/2021	
		Controlled Phase 3 Study of Abemaciclib plus Standard								
		Adjuvant Endocrine Therapy in Participants with High-Risk,								
		Node-Positive, HR+, HER2+ Early Breast Cancer Who Have								
		Completed Adjuvant HER2 Targeted Therapy								
20/YH/0061	265127	A multicentre, randomised controlled trial to evaluate the		10/12/2021	14/07/2021	07/04/2020	24/11/2021	24/11/2021		NHS Provider
		efficacy of autologous haematopoietic stem cell								
		transplantation versus alemtuzumab or ocrelizumab in								
		relapsing remitting multiple sclerosis.								
21/HRA/3072	302634	A Phase III, Multicentre, Randomised Trial Comparing SARS-	08/08/2021	14/07/2021	27/07/2021		05/08/2021	05/08/2021	05/08/2021	
		CoV-2 Re-Boost Vaccine Strategies in Immunocompromised								
		Patients								
21/LO/0651	291565	Remote Acute Assessment of Patients with High		15/07/2021	04/11/2021	02/11/2021	08/12/2021	08/12/2021	08/12/2021	
		Cardiovascular Risk Post-Acute Coronary Syndrome								
21/WA/0195	294538	A Phase III, Open Label, Randomised, 3-Arm, Multi-Centre		08/06/2021	01/09/2021	17/08/2021	13/01/2022	17/01/2022		Sponsor
		Study of Savolitinib plus Durvalumab versus Sunitinib and								
		Durvalumab Monotherapy in Participants with MET-Driven,								
		Unresectable and Locally Advanced or Metastatic Papillary								
		Renal Cell Carcinoma (PRCC) (SAMETA)								
19/EE/0228	260350	Sugar or Salt (SOS) Trial: Hyperosmolar therapy in traumatic		06/07/2021	14/12/2021	18/12/2019				
		brain injury								
20/LO/1285	285539	Phase 3 study evaluating the safety and efficacy of an		11/05/2021	02/09/2021	09/02/2021	08/12/2021	09/12/2021		Sponsor
		investigational drug (Debio 1143) in combination with								
		standard platinum-based concomitant chemoradiotherapy for								
		patients who are treatment naive, inoperable locally								
		advanced squamous cell carcinoma of the head and neck								
		(LA-SCCHN)								
19/NW/0158	259931	A multi-centre prospective randomised superiority trial of		06/07/2021	07/07/2021	25/03/2019				Sponsor
		operative fixation versus non-operative treatment for medial								·
		epicondyle fractures of the humerus in children.								
21/NW/0129	297718	A Phase 2 Study to Assess the Efficacy and Safety of AX-8		30/06/2021	02/07/2021		10/06/2021	20/08/2021	20/08/2021	Sponsor
		in Patients with Chronic Cough								
21/LO/0467	300194	A dose confirmation study of FLT180a (adeno-associated		29/06/2021	15/11/2021	19/08/2021				
		viral vector								
		containing the Padua variant of a codon-optimized human								
		Factor IX gene) in adult								
		subjects with hemophilia B - FLT180a-06								
21/LO/0396	290966	A Randomized, Double-blind, Placebo-controlled, Parallel-		22/06/2021	09/07/2021	19/08/2021	07/12/2021	08/12/2021	08/12/2021	Sponsor
		group, Multicenter Study to Assess the Efficacy and Safety of								
		JNJ-63733657, an Anti-tau Monoclonal Antibody, in								
		Participants with Early Alzheimer's Disease								
21/NE/0114	301115	·	06/12/2021	16/06/2021	06/08/2021		07/09/2021	07/09/2021	23/09/2021	Neither NHS Trust
_ ,,,,_,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	55.115	safety, reactogenicity and immunogenicity of COVID-19	3, 12, 2021	0,00,2021	30,00,2021		0.,00,202.	0.,00,2021		nor Sponsor
		vaccines in pregnant women in the United Kingdom								
		The second secon								

	T	T					1	1	1		T =
21/EE/0249	1003957	A double-blind, randomized, placebo-controlled multicenter		08/06/2021	06/10/2021						Sponsor
		study to investigate efficacy and safety of elinzanetant for the									
		treatment of vasomotor symptoms over 52 weeks in									
		postmenopausal women									
21/NW/0186	1003821	A Phase 2 Study to Evaluate the Efficacy and Safety of		14/06/2021	14/06/2021	26/07/2021	25/10/2021	02/11/2021		19/11/2021	Sponsor
		Belzutifan (MK-6482, formerly PT2977) Monotherapy in									
		Participants with Advanced									
		Pheochromocytoma/Paraganglioma (PPGL) or Pancreatic									
		Neuroendocrine Tumor (pNET)									
21/NS/0078	295820	Conduction System Pacing Optimized Therapy		29/04/2021	19/11/2021	14/09/2021	01/12/2021	01/12/2021		13/01/2022	
21/LO/0216	292031	Duroplasty for Injured cervical Spinal Cord with Uncontrolled		15/06/2021	16/06/2021	24/05/2021	17/11/2021	26/11/2021		02/12/2021	Sponsor
		Swelling									
21/LO/0297	296568	Efficacy and safety investigation of NNC0194-0499 co-		08/07/2021	02/09/2021		01/10/2021	01/10/2021		06/10/2021	Sponsor
		administered with semaglutide in subjects with non-alcoholic									
		steatohepatitis: a dose-ranging, placebo-controlled trial									
21/NW/0039	294490	A Modu lar, Ph ase II, Open-Label, Multicentre Study to		01/04/2021	01/09/2021		14/10/2021	27/10/2021		27/10/2021	Sponsor
		Assess the Preliminary Efficacy and Safety of RXC004, in									
		Patients with Advanced Solid Tumours that have Progressed									
		following Therapy with Current Standard of Care									
21/EE/0084	289545	PRotocolised Evaluation of permiSSive blood pressure	12/12/2021	03/05/2021	04/06/2021		04/06/2021	03/11/2021		29/11/2021	Sponsor
		targets versus Usual caRE. Evaluating the clinical and cost									
		effectiveness of using a permissive blood pressure target to									
		guide titration of vasoactive drugs in critically ill children with									
		hypotension.									
21/LO/0558	299581		05/01/2022	28/06/2021	16/09/2021	16/09/2021	06/12/2021	07/12/2021		17/12/2021	Sponsor
		cross-over study in healthy volunteers									
19/SC/0344	263202	Global SYMPLICITY Registry (GSR) Denervation Findings in	09/11/2021	02/04/2021	21/07/2021	07/07/2021	30/09/2021	07/10/2021		26/10/2021	Sponsor
		Real World (DEFINE) is referred to as the GSR DEFINE									
		study.									
21/FT/0062	297859	A Phase 1b/2a Study of VB119 in Adult Subjects with		16/06/2021	19/10/2021	24/06/2021		07/12/2021			Sponsor
		Primary Membranous Nephropathy						/ /			
20/EE/0293	276366	Vitrectomy and subretinal TPA for submacular haemorrhage		28/05/2021	10/06/2021	19/02/2021	14/09/2021	14/09/2021		09/11/2021	Sponsor
00/2014/0400		secondary to wet AMD (TIGER)		07/04/0004	0=/40/0004	10/11/0001					
20/NW/0438	287737	A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-		27/04/2021	07/12/2021	12/11/2021					
		Controlled, Parallel-Group Study with an Open-Label									
		Extension to Evaluate the Efficacy and Safety of Oral									
		Rilzabrutinib (PRN1008) in Adults and Adolescents with									
		Persistent or Chronic Immune Thrombocytopenia (ITP)-									
00 00 00 00 00	07.1700	PRN1008-018	20/40/2024	10/07/0004	00/00/0004	00/40/000	10/10/0001	40/40/0004		40/40/0004	
20/WM/0219	251596	Multi-Centre, open-label, randomised, prospective trial to	22/12/2021	12/05/2021	22/06/2021	09/10/2020	13/10/2021	18/10/2021		18/10/2021	Sponsor
		assess efficacy and safety of the CADDIE artificial									
00/00/00==	00/00:	intelligence system for improving endoscopic quality		4.4/05/2003	00/00/000	0.4/0.4/0.004	00/07/2224	07/06/2224		10/10/2221	
20/SC/0277	281231	A PHASE III MULTICENTER, RANDOMIZED, DOUBLE-		14/05/2020	06/08/2021	04/01/2021	29/07/2021	27/08/2021		13/10/2021	Sponsor
		BLIND, DOUBLE-DUMMY, PARALLEL-GROUP STUDY TO									
		EVALUATE THE EFFICACY AND SAFETY OF									
		FENEBRUTINIB COMPARED WITH OCRELIZUMAB IN									
		ADULT PATIENTS WITH PRIMARY PROGRESSIVE									
		MULTIPLE SCLEROSIS									

21/LO/0279	291449	Does a guided relaxation audio track increase yield of	11/11/2021	12/05/2021	11/10/2021			08/11/2021	09/11/2021	1
21/L0/02/9	291449	expressed milk in mothers of very preterm infants? A	11/11/2021	12/05/2021	11/10/2021			06/11/2021	09/11/2021	
		randomised controlled trial and nested exploratory work								
16/EM/0186	173279	Can we Save the rectum by watchful waiting or TransAnal		20/04/2021	24/06/2021					Neither NHS Trust
10/EIVI/U100	1/32/9	surgery following (chemo) Radiotherapy versus Total		20/04/2021	24/06/2021					nor Sponsor
		mesorectal excision for early REctal Cancer								noi Sponsoi
20/NS/0140	290159	ROWTATE: Randomised Controlled Trial of Specialist		31/03/2021	08/10/2021		01/09/2021	15/12/2021		Changer
20/115/0140	290159	· ·		31/03/2021	06/10/2021		01/09/2021	15/12/2021		Sponsor
		Vocational Rehabilitation and Psychological Support to								
20YH/0232	200405	Enhance Return to Work after Trauma Work Package 3		17/05/2021	17/05/2021	22/10/2020	14/09/2021	14/09/2021	25/40/2024	Chancer
2017/0232	280105	ATNEC – A randomised trial investigating the requirement		17/05/2021	17/05/2021	22/10/2020	14/09/2021	14/09/2021	25/10/2021	Sponsor
		for axillary treatment, after chemotherapy, for patients with								
00/NIM/0040	4000005	early stage breast cancer		40/05/0004	45/00/0004	40/00/0000	00/00/0004	0.4/0.0/0.004	00/40/0004	0
20/NW/0340	1003335	A PHASE IIIB MULTICENTER, RANDOMIZED, DOUBLE-		10/05/2021	15/06/2021	18/09/2020	20/08/2021	24/08/2021	03/12/2021	Sponsor
		BLIND, CONTROLLED STUDY TO EVALUATE THE								
		EFFICACY, SAFETY AND PHARMACOKINETICS OF A								
		HIGHER DOSE OF OCRELIZUMAB IN ADULTS WITH								
20/00/00	200072	PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS		22/02/2024	40/05/0004		00/40/2024	40/40/0004	40/40/2024	Chancer
20/SC/0326	286972	A Randomized, Open-Label, Phase 3 Trial of Epcoritamab vs		23/02/2021	12/05/2021		08/10/2021	12/10/2021	19/10/2021	Sponsor
		Investigator's Choice Chemotherapy in								
		Relapsed/Refractory Diffuse								
04/NIM/0055	4000500	Large B-cell Lymphoma A Phase 2/3, Multicenter, Randomized, Double-blind,		00/00/0004	07/40/0004	07/05/0004	4.0/4.0/0004	45/40/0004	00/04/0000	0
21/NW/0055	1003596			23/03/2021	27/10/2021	07/05/2021	10/12/2021	15/12/2021	06/01/2022	Sponsor
		Placebo-Controlled, Adaptive Design Study to Evaluate the								
		Efficacy and Safety of MK-5475 in Adults with								
00/00/0400	000050	Pulmonary Arterial Hypertension		05/05/0004	05/05/0004		00/07/0004	05/07/0004	40/40/0004	0
20/SC/0403	288652	PROphylaxis for paTiEnts at risk of COVID-19 infecTion		05/05/2021	05/05/2021		06/07/2021	05/07/2021	16/12/2021	Sponsor
21/YH/0191	298744	Skeletal muscle-derived cell implantation for the treatment of		13/08/2021	03/09/2021					NHS Trust
		fecal incontinence: a phase III, randomized, controlled,								
		double blind, two-armed clinical study.								-
21/WS/0080	1003802	FORWARDS; Evaluating the safety of acute baclofen in	11/01/2022	16/06/2021	13/08/2021		25/11/2021	26/11/2021	06/12/2021	Sponsor
		methadone-maintained individuals with opiate dependence								
21/FT/0050	294543	A randomised double-blind placebo-controlled clinical trial		29/04/2021	01/06/2021	20/05/2021	11/10/2021	13/10/2021		Sponsor
		investigating the effect and safety of oral semaglutide in								
		subjects with early AlzheimerÂ's disease (EVOKE plus)								
21/FT/0049	294544	A randomized double-blind placebo-controlled clinical trial		12/03/2021	24/05/2021	20/05/2021	11/10/2021	13/10/2021		Sponsor
		investigating the effect and safety of oral semaglutide in								
		subjects with early Alzheimer´s disease (EVOKE)								
18/NW/0432	239796	Safety and pharmacokinetics of ODM-208 in patients with		03/03/2021	16/07/2021	03/09/2018	07/09/2021	17/09/2021	20/09/2021	Sponsor
		metastatic castration-resistant prostate cancer								
21/EM/0102	294776	A Phase 2, Double-Blind, Randomized, Placebo-Controlled		14/05/2021	23/07/2021			11/10/2021	03/12/2021	Neither NHS Trust
		Study to Evaluate the Efficacy and Safety of Ravulizumab in								nor Sponsor
		Adult Participants With Proliferative Lupus Nephritis (LN) or								
		Immunoglobulin A Nephropathy (IgAN)								
19/SW/0209	257547	Proper Understanding of Recurrent Stress Urinary		19/04/2021	24/11/2021	19/12/2019				
		Incontinence Treatment in Women: A Randomised								
		Controlled Trial of Endoscopic and Surgical Treatment								

21/LO/0454	296522	INVESTIGATING THE IMPACT OF FAECAL MICROBIOTA TRANPSLANT ON THE CLINICAL PHENOME OF PATIENTS WITH NON-ALCOHOLIC FATTY LIVER DISEASE AND FIBROSIS	15/04/2021	22/10/2021	18/08/2021					Sponsor
20/LO/0027	263262	CONCEPT STUDY: COmparing the effectiveness of phacoemulsificatioN + ECP lasEr and Phacoemulsification alone for the treatment of primary open angle glaucoma in patients with cataract – a randomised controlled Trial	16/04/2021	12/05/2021	24/02/2020	28/06/2021	29/06/2021		15/07/2021	Sponsor
21/WS/0036	1003558	A Phase 3, Randomized, Open-Label, Controlled, Multicenter Study of Zandelisib (ME-401) in Combination with Rituximab Versus Standard Immunochemotherapy in Patients with Relapsed Indolent Non-Hodgkin's Lymphoma (iNHL) â€" The COASTAL Study	21/10/2020	21/04/2021						Sponsor
21/PR/0767	297548	Autonomous telephone follow-up after cataract surgery	18/06/2021	18/06/2021	01/07/2021	30/09/2021	30/09/2021		30/09/2021	Sponsor
21/NI/0032		A PHASE III, OPEN-LABEL, RANDOMIZED STUDY OF ATEZOLIZUMAB WITH LENVATINIB OR SORAFENIB VERSUS LENVATINIB OR SORAFENIB ALONE IN HEPATOCELLULAR CARCINOMA PREVIOUSLY TREATED WITH ATEZOLIZUMAB AND BEVACIZUMAB	08/03/2021	20/04/2021	05/05/2021	04/08/2021	09/08/2021		15/09/2021	Neither NHS Trust nor Sponsor
21/SC/0121	294861	HElping Alleviate the Longer-term consequences of COVID- 19(HEAL-COVID): a national platform trial	1 12/04/2021	30/04/2021		05/07/2021	05/07/2021		08/07/2021	Sponsor
20/WA/0121	276396	British Heart Foundation Randomised Clinical Trial of Cerebral Embolic Protection in Transcatheter Aortic Valve Implantation (BHF PROTECT-TAVI)	18/02/2021	16/08/2021	28/05/2020	21/09/2021	13/10/2021		17/12/2021	Sponsor
19/WA/0019	247285	Reduction Of Surgical Site Infection using several Novel Interventions	31/03/2021	07/04/2021	04/07/2019	06/12/2021	07/12/2021		11/01/2022	Sponsor
20/HRA/6152	292509	The LAVA (Lateral flow Antigen Validation and Applicability) 2 Study for COVID-19	30/03/2021	12/08/2021		14/09/2021	14/09/2021			Sponsor
21/NW/0149	296372	Cryoanalgesia for rib fracture pain	31/03/2021	23/07/2021	23/07/2021	16/09/2021	16/09/2021		16/09/2021	NHS Trust
21/WM/0013	283141	Hysteroscopic Excision of Leiomyoma and Polyp in Infertility	04/03/2021	25/05/2021				Site declined		
21/EE/0055	1003560	A PHASE IIB, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF INTRAVENOUS PRASINEZUMAB IN PARTICIPANTS WITH EARLY PARKINSON'S DISEASE	18/03/2021	21/07/2021	06/05/2021		27/07/2021		17/09/2021	Sponsor
21/EE/0039	290104	A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL, ACTIVE-CONTROLLED STUDY OF TRASTUZUMAB DERUXTECAN (T-DXd) VERSUS TRASTUZUMAB EMTANSINE (T-DM1) IN SUBJECTS WITH HIGH-RISK HER2-POSITIVE PRIMARY BREAST CANCER WHO HAVE RESIDUAL INVASIVE DISEASE IN BREAST OR AXILLARY LYMPH NODES FOLLOWING NEOADJUVANT THERAPY	09/02/2021	28/07/2021		17/09/2021	22/10/2021		28/10/2021	Neither NHS Trust nor Sponsor
21/LO/0177	290367	A Phase 3, Randomized, Double-blind, Active-Control Study of CPI-0610 and Ruxolitinib vs. Placebo and Ruxolitinib in JAKi Treatment Naive MF Patients	13/01/2021	08/03/2021		30/09/2021	07/10/2021		18/10/2021	Sponsor

21/SC/0084	293797	A Phase 3 Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Remdesivir in Participants with Severely Reduced Kidney Function who are Hospitalized for COVID-19	15/10/2021	05/03/2021	05/03/2021		19/04/2021	06/05/2021		27/05/2021	Neither NHS Trust nor Sponsor
20/LO/1061	276250	Attentional Therapy for the TrEatment of Neglect Disorder (ATTEND)		05/03/2021	07/06/2021		13/07/2021	13/07/2021		15/09/2021	Sponsor
20/EE/0043	269050	The effectiveness and risks of Treating people with Idiopathic Pulmonary fibrosis with the Addition of Lansoprazole (TIPAL): a randomised placebo-controlled multi-centre clinical trial		25/05/2021	25/05/2021		14/04/2021	17/01/2022		17/01/2022	
20/EE/0127	277059	The HUmeral SHaft fracture trial: A multi-centre prospective randomised superiority trial of surgical versus non-surgical interventions for humeral shaft fractures in patients aged 18 years or older		16/02/2021	16/02/2021	02/06/2020	07/06/2021	17/06/2021		29/07/2021	Both NHS Trust and Sponsor
21/HRA/0489	294480	OCTAVE: Observational Cohorts Trial - T-cells Antibodies and Vaccine Efficacy in SARS-CoV-2	17/03/2021	17/02/2021	05/03/2021		09/03/2021	09/03/2021		10/03/2021	
20/ES/0122	1003500	Efficacy and Safety Assessment of T4030 Eye Drops versus Ganfort® UD in Ocular Hypertensive or Glaucomatous Patient		09/02/2021	09/02/2021		24/09/2021	28/09/2021			Sponsor
21/FT/0040	291127	A RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, MULTICENTER, PHASE 2 STUDY TO EVALUATE THE EFFICACY, SAFETY, AND PHARMACOKINETICS OF ROZANOLIXIZUMAB IN ADULT STUDY PARTICIPANTS WITH LEUCINE-RICH GLIOMA INACTIVATED 1 AUTOIMMUNE ENCEPHALITIS		24/03/2021	30/07/2021	17/05/2021					NHS Trust
21/LO/0261	291828	Multi-centre, pilot study evaluating the feasibility, acceptability and short-term outcomes of a tailored, virtual, home-based, multicomponent prehabilitation programme in patients undergoing abdominal aortic aneurysms (AAA) repair		11/02/2021	18/05/2021	10/05/2021	29/07/2021	03/08/2021		04/08/2021	Sponsor
21/WS/0079	291666	Improving mental health following early pregnancy loss using a brief cognitive task: a randomised controlled study	09/12/2021	23/04/2021	21/10/2021	27/07/2021	22/11/2021	23/11/2021			Sponsor
20/WS/0171	281799	Physiologic Pacing Registry		28/01/2021	08/02/2021				Site declined		
19/WS/0107	256189	A pivotal study of derazantinib in patients with inoperable or advanced intrahepatic cholangiocarcinoma and FGFR2 gene fusions or FGFR2 gene mutations or amplifications		01/02/2021	02/03/2021	05/11/2019	27/05/2021	03/08/2021		12/08/2021	Neither NHS Trust nor Sponsor
21/WA/0030	293576	A randomised controlled trial of scanning eye training as a rehabilitation choice for hemianopia after stroke (SEARCH)		29/01/2021	01/02/2021	12/03/2021	28/05/2021	01/06/2021		01/06/2021	NHS Trust
21/SS/0007		A Phase III, Multicenter, Open-Label, Randomized Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination with Pomalidomide and Dexamethasone (B-Pd) versus Pomalidomide plus Bortezomib and Dexamethasone (PVd) in Participants with Relapsed/Refractory Multiple Myeloma (DREAMM 8)			02/02/2021		08/06/2021	01/07/2021		16/07/2021	Neither NHS Trust nor Sponsor
21/EE/0017	282284	ELEVATE: Temozolomide + nivolumab in MGMT deficient oesophagogastric cancer		25/01/2021	25/01/2021				Site declined		

04/57/0050	000000	A Dhana 4 Chudu Fumlada a tha Cafata Talanahilita	04/44/0004	00/04/0004	40/05/0004	47/05/0004	04/00/0004	00/00/0004		05/40/0004	NUIC Tourst
21/FT/0058		A Phase 1 Study Exploring the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099318	04/11/2021	29/04/2021	18/05/2021	17/05/2021	24/09/2021	28/09/2021		25/10/2021	NHS Trust
		in Participants With Select Advanced Solid Tumors									
20/EE/0254	202002	AN OPEN-LABEL, MULTICENTER, RANDOMIZED PHASE		29/12/2020	20/01/2021	20/01/2021	10/06/2021	24/06/2021		18/06/2021	Neither NHS Trust
20/66/0234	203093	3 STUDY OF FIRST-LINE ENCORAFENIB PLUS		29/12/2020	20/01/2021	20/01/2021	10/00/2021	24/00/2021		10/00/2021	nor Sponsor
		CETUXIMAB WITH OR WITHOUT CHEMOTHERAPY									noi sponsoi
		VERSUS STANDARD OF CARE THERAPY WITH A									
		SAFETY LEAD-IN OF ENCORAFENIB AND CETUXIMAB									
		PLUS CHEMOTHERAPY IN PARTICIPANTS WITH									
		METASTATIC BRAF V600E-MUTANT COLORECTAL									
		CANCER									
21/SC/0017		MultiStemÃ,® Administration for Stroke Treatment and		03/03/2021	25/08/2021				Site declined		
21/00/0017	200001	Enhanced Recovery Study		00/00/2021	20/00/2021						
20/SC/0377	287169	Recombinant Factor VIIa for Acute Hemorrhagic Stroke		03/03/2021	03/03/2021				Site declined		
		Administered at Earliest Time (FASTEST) Trial									
20/HRA/6338	293815	A randomised, multicentre post-exposure prophylaxis (PEP)		13/01/2021	19/02/2021			15/03/2021			Neither NHS Trust
		clinical trial evaluating RESP301, an inhaled therapy for									nor Sponsor
		treatment of lung infections, for prevention of onward									
		transmission of viral infections including SARS-CoV-2 to									
		household members.									
20/SC/0372	283157	Intramuscular tranexamic acid for the treatment of		05/01/2020	26/05/2021	17/12/2020					Sponsor
		symptomatic mild traumatic brain injury in older adults: a									
		randomized, double-blind, placebo-controlled trial.									
20/SC/0450	291949	A Placebo-Controlled, Double-Blind, Parallel-Treatment Arm,		14/12/2020	17/08/2021	01/03/2021		09/12/2021			Sponsor
		216 Week Study to Evaluate Efficacy and Safety of									
		Treatment With BAN2401									
		in Subjects With Preclinical Alzheimer's Disease and									
		Elevated Amyloid (A45 Trial) and in Subjects With Early									
		Preclinical Alzheimer's Disease and Intermediate									
20/NW/0383		Amyloid (A3 Trial) A Phase 3 Randomized, Double-Blind Placebo-Controlled		24/12/2020	02/01/2021		4.0/00/2024	4.0/00/2024		20/02/2024	Cnanas
20/1977/0383	287807	· · · · · · · · · · · · · · · · · · ·		24/12/2020	02/01/2021		16/02/2021	16/02/2021		26/02/2021	Sponsor
		Trial to Evaluate the Efficacy and Safety of Remdesivir (GS-									
19/EE/0377	266504	5734TM) Treatment of COVID-19 in an Outpatient Setting Trial of Ondansetron as a Parkinson's HAllucinations	08/10/2021	07/12/2020	01/02/2021		08/04/2021	08/04/2021		08/06/2021	Sponsor
19/66/03/7		Treatment	06/10/2021	07/12/2020	01/02/2021		06/04/2021	00/04/2021		00/00/2021	Sponsor
20/NW/0300	285728	A Phase 3, randomized, double-blind, efficacy and safety		23/11/2020	01/09/2021	15/09/2020	30/09/2021	30/09/2021		17/11/2021	Neither NHS Trust
		study comparing SAR442168 to placebo in participants with									nor Sponsor
		nonrelapsing secondary progressive multiplesclerosis									
		(HERCULES)									
21/WA/0103	291833	INTERvention with Cerebral Embolic Protection in	29/07/2021	22/02/2021	27/04/2021	20/04/2021	03/06/2021	08/06/2021		08/06/2021	Sponsor
		Transcatheter Aortic Valve Implantation (INTERCEPTavi):									
		â€~Carbon-Dioxide Flushing versus Saline Flushing of									
		Transcatheter Aortic Valves: A Single-centre Randomised Controlled Trial'									
20/LO/1291	292074	The effect of semaglutide in subjects with non-cirrhotic non-		03/12/2020	02/03/2021		17/03/2021	13/04/2021		16/04/2021	Neither NHS Trust
20/10/1281	232014	alcoholic steatohepatitis		03/12/2020	02/03/2021		17/03/2021	13/04/2021		10/04/2021	nor Sponsor
21/LO/0203	288725	ORBITA-COSMIC: Coronary sinus reducer Objective impact	21/05/2021	04/02/2021	29/03/2021	27/03/2021	21/05/2021	21/05/2021		21/05/2021	
		on Symptoms, MRI Ischaemia and microvascular Resistance									

21/LO/0520	294670	Lead EvaluAtion for Defibrillation and Reliability(LEADR)		19/11/2020	08/11/2021	03/11/2021	30/11/2021	30/11/2021	09/12/2021	
20/LO/1129	1003422	A Phase 2 study to evaluate the safety and efficacy of EP0057 in combination with Olaparib in advanced ovarian cancer patients who have: Cohort 1 – platinum resistant disease and are PARP inhibitor naà ve; Cohort 2 – had at least 2 prior lines of therapy which must include at least 1 line of platinum-based chemotherapy followed by PARP inhibitor maintenance.	10/11/2021	17/11/2020	29/06/2021	21/12/2020	30/07/2021	06/08/2021	12/08/2021	Sponsor
18/LO/2070	246179	TAPS2: Transfusions Antenatally in Pregnant women with SCD		16/10/2020	14/07/2021	23/10/2019	06/10/2021	06/10/2021	28/10/2021	Sponsor
20/WM/0297	288227	A Phase 3, Open-label, Single Arm, Multicenter Study of Ravulizumab in Addition to Best Supportive Care in Pediatric Participants (from 1 month to < 18 years of age) with Thrombotic Microangiopathy (TMA) after Hematopoietic Stem Cell Transplantation (HSCT)		09/11/2020	10/08/2021					Sponsor
20/NI/0070	1003313	Brain Re-Irradiation Or Chemotherapy: a phase II randomised trial of re-irradiation and chemotherapy in patients with recurrent glioblastoma		07/10/2020	07/06/2021	07/07/2020	12/08/2021	07/12/2021		NHS Trust
20/NW/0487	289272	Do the results of intra-operative margin assessment correlate with the output of conventional histology for patient undergoing breast conservation surgery?	04/06/2021	15/12/2020	11/01/2021	18/01/2021	14/05/2021	27/05/2021	01/06/2021	Neither NHS Trust nor Sponsor
21/SW/0016	1003529	A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Compare the Efficacy and Safety of Sotatercept Versus Placebo When Added to Background Pulmonary Arterial Hypertension (PAH) Therapy for the Treatment of PAH.		15/02/2021	09/11/2021	22/03/2021	18/11/2021	23/11/2021	06/12/2021	
21/LO/0366	290747	Intra-operative ultrasound guided laparoscopic ovarian cystectomy (UGLOC) in the management of benign ovarian cysts: Randomised Controlled Trial	16/11/2021	19/10/2020	15/08/2021	13/08/2021	15/11/2021	15/11/2021	15/11/2021	Sponsor
20/NW/0463	1003437	Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma	21/09/2021	10/09/2020	17/05/2021		19/04/2021	02/06/2021	16/06/2021	Neither NHS Trust nor Sponsor
21/LO/0051	285417	Diagnosis of Heart Failure in the Post-COVID-19 Clinic, Primary Care and Hospital Setting Using a Digital Stethoscope with AI ECG	15/04/2021	19/10/2020	29/03/2021	05/02/2021	13/04/2021	15/04/2021	15/04/2021	
21/NW/0175	280580	Omnipolar Voltage-Based Substrate Characterisation of the Left Atrium in Persistent Atrial Fibrillation.	06/09/2021	19/10/2020	04/08/2021	20/07/2021	06/07/2021	13/08/2021	13/08/2021	
20/LO/0840	264482	Functional and Ultrasound guided Resection of Glioblastoma. A two stage trial. Stage 1 â€" Non-randomised collaborative learning and evaluation phase of participating centres (IDEAL Stage 2b study), followed by Stage 2 â€" A Multicentre Phase III trial with 2 mechanistic substudies.	15/06/2021	16/10/2020	30/04/2021	05/10/2020	12/05/2021	12/05/2021	24/05/2021	
20/LO/0196	271343	PreOperative Endocrine Therapy for Individualised Care with Abemaciclib		05/10/2020	29/04/2021	08/07/2020	29/04/2021	08/07/2021	19/07/2021	Neither NHS Trust nor Sponsor

20/LO/1157	281627	An anon label randomized controlled phase 2 study of	04/11/2021	09/10/2020	15/07/2021	17/12/2020	17/09/2021	12/10/2021	27/10/2021	Neither NHS Trust
20/LO/1157	201027	An open-label, randomized, controlled phase 3 study of enfortumab vedotin in combination with pembrolizumab with	04/11/2021	09/10/2020	15/07/2021	17/12/2020	17/09/2021	12/10/2021	27/10/2021	nor Sponsor
		or without chemotherapy, versus chemotherapy alone in								Tior oponsor
		previously untreated locally advanced or metastatic urothelial								
		cancer								
20/LO/1106	286152		04/08/2021	23/09/2020	11/01/2021		05/02/2021	09/04/2021	26/04/2021	Neither NHS Trust
		Pharmacokinetic, and Pharmacodynamic Study of								nor Sponsor
		Tilvestamab (BGB149) in Relapsed, Platinum-resistant, High-								·
		grade Serous Ovarian Cancer (HGSOC) Patients								
19/EE/0384	275752	VenaSeal Spectrum: Global, Post-Market, Prospective, Multi-	20/08/2021	01/09/2020	11/02/2021	06/04/2020	30/06/2021	19/07/2021	11/08/2021	Neither NHS Trust
		Center, Randomized Controlled Trial of the VenaSealâ,,¢								nor Sponsor
		Closure System vs. Surgical Stripping or Endothermal								
		Ablation (ETA) for the Treatment of Early and Advanced								
		Stage Superficial Venous Disease								
21/YH/0056	283442	Prediction of Patient Drug Response Using an Ex Vivo Organ		13/05/2021	01/11/2021	08/04/2021				
		Culture (EVOC) on fresh human tumour samples from								
		Metastatic Patients					/ /	/ /		
20/LO/1115	286901	Phase 2, Double-blind, Randomized, Placebo-controlled		04/04/2021	02/07/2021		14/07/2021	11/08/2021	16/08/2021	Sponsor
		Study of HepTcell (Adjuvanted FP-02.2) as an								
		Immunotherapeutic Vaccine in Treatment naÃf¬ve								
20/1 0/0040	070404	Patients with Inactive Chronic Hepatitis B (CHB)		40/07/2024	24/42/2024		40/04/0000	14/01/2022		
20/LO/0848	272164	ALLTogether1 – A Treatment study protocol of the ALLTogether Consortium		12/07/2021	21/12/2021		13/01/2022	14/01/2022		
		for children and young adults (1-45 years of age) with newly								
		diagnosed acute								
		lymphoblastic leukaemia (ALL)								
20/NE/0283	286210	An Open-Label, Randomized, Controlled, Phase 2 Study to		28/01/2021	13/04/2021		28/04/2021	29/04/2021		Neither NHS Trust
20/11/0200	200210	Evaluate the Safety and Efficacy of APL-2 in the Treatment		20/01/2021	10/04/2021		20/04/2021	20/04/2021		nor Sponsor
		of Post-Transplant Recurrence of C3G or IC-MPGN								оролоол
20/LO/0504	1003208	·		16/09/2020	29/06/2021		17/09/2021	21/09/2021	18/11/2021	Neither NHS Trust
		Ursodeoxycholic Acid compared to Metformin to Reduce								nor Sponsor
		effects of Diabetes mellitus								
21/PR/0712	287896	A feasibility study of novel viricidal personal protective		01/11/2020	02/03/2021	07/06/2021	19/10/2021	19/10/2021	19/10/2021	Neither NHS Trust
		equipment for preventing COVID-19 transmission								nor Sponsor
21/SC/0094	289344	A phase I study to determine safety and immunogenicity of	18/10/2021	16/03/2021	10/08/2021	22/04/2021	19/08/2021	20/08/2021	23/09/2021	Sponsor
		the candidate COVID-19 vaccine ChAdOx1 nCoV-19								
		delivered by aerosol in healthy adult volunteers								
20/EM/0298	283692	Ultrasound Prediction of Delivery Mode: can the first stage	17/05/2021		12/04/2021	18/02/2021		12/05/2021	14/05/2021	
		prediction model be further improved?								
21/PR/0250	281309		09/07/2021	11/09/2020	13/05/2021	12/05/2021	07/07/2021	07/07/2021	07/07/2021	
		and vascular surgery - a pilot randomised clinical study			0.7/0.7/0.07/	27/22/222/				
20/LO/1272	287235	A prospective randomised extended pilot study of a directed	02/07/2021		25/03/2021	25/03/2021		13/04/2021	13/04/2021	Sponsor
		psycho-educational tool to prevent psychological sequelae								
20/1 0/2022	262000	following Paediatric Intensive Care admission		24/09/2022	05/04/2024		00/02/2024	00/02/2024	10/04/2024	Noith or NUIC Trust
20/LO/0009	263698	Observational cohort with embedded Randomised Controlled		24/08/2020	05/01/2021		09/02/2021	09/02/2021	19/04/2021	Neither NHS Trust
		trials to study pregnancy-Associated progression of Renal								nor Sponsor
		Disease – A Feasibility Study of Dietary Nitrate (BEETroot juice) to protect kidney function in pregnant women with								
		Chronic Kidney Disease								
		Official Mulicy Disease		l	<u> </u>			<u> </u>		

20/LO/1297	288071	Impact of the short chain fatty acid propionate on mesenteric adipose tissue, liver metabolism and insulin sensitivity: The PROMIS study.		08/03/2021	08/03/2021	25/01/2021	08/03/2021	26/10/2021	26/10/2021	Sponsor
18/WA/0420	246637	Spironolactone for Adult Female Acne: A pragmatic multicentre double-blind randomised superiority trial to investigate the clinical and cost-effectiveness of spironolactone for moderate or severe persistent acne in women	25/05/2021	20/11/2020	13/04/2021	04/02/2019	13/05/2021	13/05/2021	21/05/2021	
20/LO/1111	286572	PerFormance of the EMBOVACTM Aspiration Catheter for Neurothrombectomy: A Postâ€Market Clinical Followâ€up Trial.	04/06/2021	21/07/2020	18/03/2021		13/04/2021	19/04/2021	24/05/2021	Sponsor
21/NI/0009	278082	Accuracy of ECG-guided tip placement and point of care ultrasound scan (POC-US) during central line insertion in neonates – a feasibility study CLIN study	23/06/2021		04/02/2021	27/01/2021		25/05/2021		Neither NHS Trust nor Sponsor
20/LO/0745	273024	Phase 1 / 2 Multicenter Study of the Safety, Pharmacokinetics, and Preliminary Efficacy of APL-101 in Subjects with Non-Small Cell Lung Cancer with c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors	15/07/2021	07/07/2020	09/03/2021	09/06/2020	30/03/2021	31/03/2021		Neither NHS Trust nor Sponsor
20/YH/0268	287353	An open label, single arm study to evaluate single and multiple dose pharmacokinetics, safety and tolerability, and to explore clinical outcomes of treatment with intravenous (IV) zanamivir in neonates and infants under 6 months of age with confirmed complicated influenza infection		06/07/2020	05/05/2021		29/07/2021	04/08/2021		Sponsor
20/NW/0312	284188	A Registry-based, Randomised, Double-blind, Placebo- Controlled Cardiovascular Outcomes Trial to Evaluate the Effect of Dapagliflozin on the Incidence of Heart Failure or Cardiovascular Death in Patients without Diabetes with Acute Myocardial Infarction at Increased Risk for Subsequent Development of Heart Failure.	10/12/2021	22/10/2020	17/08/2021	23/07/2020	02/08/2021	15/09/2021	28/10/2021	Sponsor
20/WM/0221	285758	LumenEye during CovID-19 (LuCID study)			05/02/2021	10/09/2020				Sponsor
20/NI/0086	1003261	A RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, MULTI-CENTER STUDY TO EVALUATE THE EFFICACY AND SAFETY OF OBINUTUZUMAB IN PATIENTS WITH ISN/RPS 2003 CLASS III OR IV LUPUS NEPHRITIS		25/11/2020	15/10/2021					Neither NHS Trust nor Sponsor
20/LO/0821	281982	AN OPEN-LABEL, MULTICENTER, ROLLOVER STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND EFFICACY OF LONG-TERM GANTENERUMAB ADMINISTRATION IN PARTICIPANTS WITH ALZHEIMER'S DISEASE	14/07/2021	02/05/2021				28/06/2021	28/06/2021	
20/LO/0906	1003020	A Phase 2b, open-label, single-arm study of ZW25 monotherapy in subjects with advanced or metastatic HER2-amplified biliary tract cancers		06/04/2020	09/03/2021		08/12/2020	14/04/2021		Neither NHS Trust nor Sponsor

20/NW/0230		A Phase 3, Multinational, Randomized, Open-Label, Three Parallel-Arm Study of PF-06801591, an anti-PD-1 antibody, in Combination with Bacillus Calmette-Guerin (BCG Induction With or Without BCG Maintenance) Versus BCG (Induction and Maintenance) in Participants with High-Risk, BCG-NaÃ-ve Non-Muscle Invasive Bladder Cancer			20/01/2021	18/06/2020	15/02/2021	25/02/2021			Neither NHS Trust nor Sponsor
20/NW/0310	267092	A randomized double-blind, placebo-controlled, multicenter trial assessing the impact of lipoprotein (a) lowering with TQJ230 on major cardiovascular events in patients with established cardiovascular disease.	23/07/2021	29/10/2019	15/04/2021	25/09/2020	29/03/2021	05/05/2021		05/07/2021	Sponsor
20/LO/1008	285155	A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Clinical Study to Evaluate the Efficacy and Safety of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH).		11/05/2020	10/08/2021	23/11/2020	01/10/2021	08/10/2021		, ,	Neither NHS Trust nor Sponsor
20/SC/0371		A Phase 111, Randomised, double-blind, Placebo-controlled study of Atezolizumab with or without Tiragolumab (anti-tigit antibody) in Patients with Unresectable Esophageal Squamous Cell Carcinoma whose cancers have not progressed following definitive Concurrent Chemoradiotherapy.		04/09/2020	18/05/2021	09/12/2020	18/06/2021	24/06/2021			Neither NHS Trust nor Sponsor
21/LO/0054	283483	A MULTICENTRE PILOT RANDOMISED CONTROL TRIAL OF AN ADAPTED MOBILE REHABILITATION SYSTEM FOR SELF-DIRECTED REHABILITATION AND IMPROVED UPPER LIMB OUTCOMES IN STROKE SURVIVORS WITH UPPER LIMB WEAKNESS	20/10/2021	26/05/2021	22/06/2021	21/05/2021	06/10/2021	06/10/2021		06/10/2021	NHS Trust
20/EM/0087	274214	An open-label, randomised, multicentre, phase III study of irinotecan liposome injection, oxaliplatin, 5-fluorouracil/leucovorin versus nab-paclitaxel plus gemcitabine in subjects who have not previously received chemotherapy for metastatic adenocarcinoma of the pancreas.	10/05/2021	01/04/2020	05/03/2021	19/05/2020	28/01/2021	20/04/2021		28/04/2021	
19/LO/0288	235544	A Randomised Placebo-Controlled Trial on the effectiveness of Escitalopram and Nortriptyline for depressive symptoms in Parkinson's disease		03/09/2020	24/02/2021	09/07/2020	08/12/2021	08/12/2021		17/12/2021	Sponsor
19/LO/1513	264579	A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO- CONTROLLED, MULTICENTER, DOSE-FINDING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF CC-90001 IN SUBJECTS WITH NON-ALCOHOLIC STEATOHEPATITIS (NASH) AND STAGE 3 OR STAGE 4 LIVER FIBROSIS		02/04/2020	13/04/2021				Sponsor declined		
21/EM/0019	273631	Improving implantable cardioverter defibrillator arrhythmia detection: development of a novel arrhythmia detection algorithm	05/07/2021	29/12/2020	21/04/2021	30/03/2021	05/07/2021	05/07/2021		05/07/2021	Sponsor

20/00/0440	070055	Due in connectivity and notices reported automatic in nearly		00/00/0000	00/04/0004		05/05/0004	40/05/0004	00/07/2024	Chanasi
20/SC/0116	272955	Brain connectivity and patient reported outcomes in people with HIV with symptoms of insomnia switching integrase		02/03/2020	08/04/2021		05/05/2021	12/05/2021	08/07/2021	Sponsor
		inhibitor-based ART; a randomised controlled study								
19/WM/0364	257918	Letrozole or Clomifene, with or without metformin, for		19/02/2020	06/10/2021	09/06/2020				Sponsor
13/ 00101/0304	23/318	ovulation induction in women with polycystic ovary		13/02/2020	00/10/2021	03/00/2020				эропзог
		1								
40/55/0000	005750	syndrome: a 2x2 factorial design randomised trial		04/00/0000	04/07/0004		04/00/0004	40/07/0004		Naith an NILIO Touat
18/EE/0389	235758	Seizure PRophylaxis IN Glioma		21/02/2020	01/07/2021		24/03/2021	19/07/2021		Neither NHS Trust nor Sponsor
20/NE/0014	272055	Multi-centre, randomised, open-label, blinded endpoint		20/02/2020	21/10/2021			21/10/2021		Sponsor
20/11/0014	2/2033	assessed, trial of corticosteroids plus intravenous		20/02/2020	21/10/2021			21/10/2021		эропзог
		•								
		immunoglobulin (IVIG) and aspirin, versus IVIG and aspirin								
		for prevention of coronary artery aneurysms in Kawasaki								
10/55/0050	0=00=4	disease		0.1/0.7/0.001	0.4.4.0.40.00.4	07/00/0000				
19/EE/0376	270371	A Double-blind, Randomized, Placebo-controlled,		21/05/2021	21/12/2021	25/02/2020				
		Parallelgroup Trial of the Efficacy and Safety of Nabiximols Oromucosal Spray as Add-on Therapy in Patients with								
		Spasticity Due to Multiple Sclerosis								
20/WS/0057	277361	Erythropoietin and Darbepoetin in Neonatal Encephalopathy	12/08/2021	01/06/2020	30/03/2021	27/05/2020	27/05/2021	28/05/2021	28/05/2021	Sponsor
20, 113,003,	277301	(EDEN) Trial	12,00,2021	01,00,2020	30,03,2021	2770372020	27/03/2021	20/03/2021	20,03,2021	эропзог
19/LO/1953	271361	Efficacy of BIC/F/TAF versus standard of care in the	17/06/2021	16/09/2020	25/05/2021		25/05/2021	01/06/2021	09/06/2021	
13/20/1333	27 1001	treatment of new HIV infection diagnoses in the context of	17700/2021	10/03/2020	25/05/2021		25/05/2021	01/00/2021	03/00/2021	
		â€rest and treat'								
19/LO/1892	272434	A multicenter, randomized, active-controlled, double-blind,		01/01/2020	13/01/2021	21/01/2020	19/04/2021	19/04/2021	22/09/2021	Sponsor
		parallel group clinical trial, investigating the efficacy, safety,		' '	' '	, ,	, ,	, ,		'
		and tolerability of continuous subcutaneous ND0612								
		infusion in comparison to oral IR-LD/CD in subjects with								
		Parkinson's disease experiencing motor fluctuations								
		(BouNDless).								
19/NW/0707	272541	,	24/06/2021	20/11/2010	02/04/2021		14/01/2021	10/05/2021	28/05/2021	Neither NHS Trust
19/14/7/07/07	212541	Study Comparing the Efficacy and Safety of Tirzepatide	24/00/2021	29/11/2019	02/04/2021		14/01/2021	10/03/2021	20/03/2021	nor Sponsor
		versus Placebo in Patients with Nonalcoholic Steatohepatitis								пог оропзог
		(NASH)								
20/LO/0608	270125	Tubal flushing with oil-based contrast during HSG in		20/08/2019	20/10/2021		08/12/2021	09/12/2021	07/01/2022	Sponsor
		subfertle women: Is early flushing effective and cost-								·
		effective as compared to delayed flushing?								
20/LO/0607	270603	Oil-based versus water-based contrast media for	20/01/2022	06/04/2021	03/05/2021	13/05/2021	15/10/2021	15/10/2021	18/10/2021	Sponsor
		hysterosalpingography (HSG) in infertile women with								,
		unevaluated indications: a randomized controlled trial								
19/YH/0049	258945	A phase 1c, multicenter, randomized, observer-blinded,		19/08/2020	02/03/2021		01/06/2019	17/06/2021	05/07/2021	Sponsor
		placebo-controlled study to evaluate the safety, tolerability,								
		pharmacokinetics, and pharmacodynamics effects of a single								
		dose of MTPS9579A in patients with asthma requiring								
		inhaled corticosteroids and a second controller								
		The second secon								
	<u> </u>		l	<u> </u>						

19/SW/0043	235625	CHIEF-PD (CHolinesterase Inhibitor to prEvent Falls in	16/06/2021	11/09/2019	18/03/2021	26/06/2019		08/04/2021	12/05/2021	Sponsor
		Parkinson's Disease): A phase 3 randomised, double-	. 0, 00, 202 .	,	. 0, 00, 202 .	_0,00,_0.0			,,	Op 6.100.
		blind placebo-controlled trial of rivastigmine to prevent falls in								
		Parkinson's disease.								
19/LO/1064	260639	The TIGHT-K STUDY. Prevention of dysrhythmias on the	16/06/2021	15/11/2019	19/04/2021	06/11/2019	26/04/2021	28/05/2021	04/06/2021	
		cardiac intensive care unit - does maintenance of high-								
		normal serum potassium levels matter?								
19/LO/1152	265415	A phase 2, open-label, single-arm, multicenter study to		02/05/2019	27/04/2021	16/08/2019	22/11/2019	06/05/2021	06/05/2021	Sponsor
		evaluate the efficacy and safety of pemigatinib in participants with previously treated locally advanced/metastatic or								
		surgically unresectable solid tumor malignancy harboring								
		activating FGFR mutations and translocations								
20/LO/0474	266759	Psilocybin as a Treatment for Restrictive Anorexia Nervosa:	28/05/2021	09/12/2020	11/01/2021	23/06/2020	12/04/2021	12/04/2021	12/04/2021	Neither NHS Trust
		A Pilot Study								nor Sponsor
19/LO/1669	266322	The RIO Trial: A randomised controlled trial of dual long-		14/01/2020	16/04/2021	12/12/2019	05/05/2020	10/05/2021	13/05/2021	Neither NHS Trust
		acting HIV-specific broadly neutralising antibodies (bNAbs)								nor Sponsor
		vs ART-only in treated primary HIV infection - A two-stage randomised phase II placebo controlled clinical trial								
17/NW/0581	214739	Does Interleukin-1 Receptor Antagonist Improve Outcome		17/04/2019	17/05/2021		13/01/2022	14/01/2022		Sponsor
17/11/1/0301	214733	following aneurysmal Subarachnoid Haemorrhage (aSAH)? A		17,04,2013	17,03,2021		15/01/2022	14/01/2022		эропзог
		Phase III trial								
18/EM/0310	239782	Emergency Cervical Cerclage to Prevent Miscarriage and		11/03/2019	25/10/2021	16/01/2019				Sponsor
		Preterm Birth - a Randomised Controlled Trial								
18/LO/1022	233151	An open-label, randomised, phase II trial of ruCaparib		06/02/2019	13/12/2021	14/05/2019	06/02/2019			
		combined with Nivolumab +/- Ipilimumab to augment								
		response in homologous repair deficient patients with								
		relapsed Ovarian, primary peritoneal and fallopian tube								
		cancer								
19/LO/0836	262145		24/06/2021	22/02/2019	07/06/2021	07/06/2021	07/06/2021	15/09/2021	15/09/2021	
		(InterCEPT): â€̃Carbon-Dioxide Flushing versus Saline Flushing of								
		Thoracic Aortic Stents: A Multi-centre Randomised								
		Controlled Trial'								
20/LO/0938	1003322	A Phase 3, Randomized, Study of Neoadjuvant and Adjuvant		07/10/2019	09/03/2021	13/11/2020	02/11/2020	18/05/2021	02/07/2021	Neither NHS Trust
		Nivolumab Plus NKTR-214,								nor Sponsor
		Versus Nivolumab Alone Versus Standard of Care in								
		Participants with Muscle-Invasive Bladder Cancer (MIBC)								
		Who								
		Are Cisplatin Ineligible								
19/SC/0144	226984	Defining personalised outcomes in pre-school children with	13/08/2021		24/02/2021	31/05/2019		19/05/2021	25/05/2021	Neither NHS Trust
		recurrent wheeze								nor Sponsor

20/LO/0345	269752	A Phase 3, Randomized, Double-blind, Placebo-controlled		25/02/2020	31/03/2021	19/06/2020				Neither NHS Trust
		Study of Ralinepag to Evaluate Safety and Effects on Exercise								nor Sponsor
		Capacity Assessed by Cardiopulmonary Exercise Testing in								
		Subjects with World Health Organization Group 1 Pulmonary								
		Hypertension Who Recently Initiated Therapy (ADVANCE								
		Capacity)								
19/LO/0062		A study evaluating the efficacy and safety of ralinepag to		24/04/2020	02/07/2021					Neither NHS Trust
		improve treatment outcomes in PAH patients.								nor Sponsor
20/PR/0378	280354	Arginine Supplementation to improve Cardiovascular and	10/06/2021	27/04/2020	12/04/2021	12/01/2021	28/07/2020	15/04/2021	17/04/2021	
		Endothelial function after NSAID Treatment (ASCENT)								
19/EE/0027	252781	PresSura Assessment of NK1 Inhibition in Traumatic Brain		14/02/2019	26/11/2021	15/10/2019				
		Injury in a Global Efficacy and Safety Trial								
17/EM/0440	230556	A randomised phase III trial to evaluate the Duration of ANti-		20/04/2018	23/09/2021	24/05/2018	20/12/2019	03/11/2021	24/11/2021	Sponsor
		PD1 monoclonal antibody Treatment in patients with								
		metastatic mElanoma								